**TW3: Annual General Mandate 2024**

On April 26, 2024, Central Pharmaceutical JSC No. 3 announced General Mandate No. 04/NQ-DHDCD as follows:

‎‎Article 1. Approve the Report on activities of the Board of Directors in 2023 and the operating orientation for 2024;

‎‎Article 2. Approve the Report on the implementation results in 2023 and the production and business plan for 2024 by the Executive Board

1. Some production and business targets achieved in 2023

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| No. | Target | Results 2022 | Plan 2023  | Results 2023  | Results 2023/Plan 2023  |
| 1 | Revenue from goods sold and services provided | 317,728,138 | 320,800,000 | 348,630,543 | 109% |
| 2 | Revenue deductions | 230,394 | 300,000 | 901,666 | 301% |
| 3 | Net revenue = (1) - (2) | 317,497,744 | 320,500,000 | 347,728,877 | 109% |
| 4 | Cost of goods sold | 276,975,339 | 279,100,000 | 308,047,898 | 110% |
| 5 | Gross profit = (3)-(4) | 40,522,404 | 41,400,000 | 39,680,979 | 96% |
| 6 | Financial investment income | 1,923,811 | 400,000 | 413,351 | 103% |
| 7 | Financial expenses: | 4,460,799 | 3,400,000 | 6,662,936 | 196% |
| 8 | Selling expense | 16,139,931 | 16,400,000 | 13,156,566 | 80% |
| 9 | General and administrative expense | 17,662,456 | 17,800,000 | 15,734,542 | 88% |
| 10 | Net operating profit =(5)+(6)-(7)-(8)-(9) | 4,183.029 | 4,200,000 | 4,540,286 | 108% |
| 11 | Other incomes: | 87,624 | 150,000 | 114,342 | 76% |
| 12 | Other expenses: | 342,709 | 200,000 | 436.858 | 218% |
| 13 | Profit before tax = (10)+(11)-(12) | 3,927,944 | 4,150,000 | 4,217,770 | 102% |
| 15 | Profit after tax =(13)-(14) | 3,149,925 | 3,280,000 | 3,289,112 | 100% |

1. Production and business plan for 2024:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| No. | Target | Results2023 | Plan2024 | Plan 2024/Results 2023  |
| 1 | Revenue from goods sold and services provided | 348,630,543 | 356,000,000 | 102% |
| 2 | Net revenue: | 347,728,877 | 355,400,000 | 102% |
| 3 | Total profit before tax | 4,217,770 | 4,450,000 | 106% |
| 4 | Profit after tax | 3,289,112 | 3,500,000 | 106% |

‎‎Article 3. Approve the Report on activities of the Supervisory Board in 2023

Article 4. Approve the Proposal of the Audited Financial Statements 2023

‎‎Article 5. Approve the Proposal for the expected profit distribution plan for 2023 and some financial targets for 2024.

Unit: VND

|  |  |  |
| --- | --- | --- |
| No. | Item | Amount |
| 1 | Profit after tax according to the audited Financial Statements in 2023 | 3,289,112,034 |
| 2 | Distribute profit after tax in 2023 as follows: |  |
|  | *Deduct Investment and Development Fund (15% of profit after tax)*  | *493,366,805* |
|  | *Deduct Bonus and Welfare Fund (10% of profit after tax)* | *328,911,203* |
|  | *Bonus for Board of Directors, Supervisory Board (according to General Mandate 2023)* | *164,911,203* |
|  | *Pay cash dividend of 5%* | *851,300,000* |
| 3 | Profit after tax in 2023 carried forward to the following year | 1,450,622,822 |

‎‎Article 6. Approve the Proposal for the report on remuneration and salary payment to the Board of Directors, Supervisory Board, General Manager and Company Secretariat in 2023 and the plan for remuneration, salary and bonus payment in 2024

‎‎Article 7. Approve the Proposal for the plan to select the audit company for 2024

‎‎Article 8. Approve the Proposal for dismissing Mr. Nguyen Van Khai from the position of member of the Board of Directors and electing an additional member of the Board of Directors for the term 2020-2025

The General Meeting voted to approve the Proposal for dismissing Mr. Nguyen Van Khai from the position of member of the Board of Directors and electing an additional member of the Board of Directors for the term 2020-2025

‎‎Article 9. Approve the Proposal for dismissing Ms. Ha Lan Anh from the position of member of the Supervisory Board and electing an additional member of the Supervisory Board for the term 2020-2025

The General Meeting voted to approve dismissing Ms. Ha Lan Anh from the position of member of the Supervisory Board and electing an additional member of the Supervisory Board for the term 2020-2025

‎‎Article 10. Elect an additional member of the Board of Directors for the term 2020-2025

The General Meeting elected Mr. Dinh Xuan Han as an additional member of the Board of Directors for the term 2020-2025.

‎‎Article 11. Elect an additional member of the Supervisory Board for the term 2020-2025

The General Meeting elected Ms. Do Hoang Giang as an additional member of the Supervisory Board for the term 2020-2025.

‎‎Article 12. Terms of enforcement

This General Mandate was approved at the Annual General Meeting of Shareholders in 2024 of Central Pharmaceutical JSC No.3, meeting session on April 26, 2024.

This General Mandate takes effect from the signing date of April 26, 2024 after being approved by the General Meeting of Shareholders, members of the Board of Directors, members of the Supervisory Board, the Board of Management and all shareholders shall execute this decision in accordance with their competence, functions and duties in compliance with the provisions of the law and the Charter of Central Pharmaceutical JSC No.3.